Grupo Argentino de Tratamiento de la Leucemia Aguda
Quick facts
Phase 3 pipeline
- ARM A: Active Comparator Drug · Oncology
This drug works by inhibiting the BCL-2 protein, preventing cancer cell survival. - ARM B: Blocks Therapy Drug · Oncology
ARM B: Blocks Therapy Drug inhibits beta-adrenergic receptors to reduce sympathetic nervous system activity in acute leukemia treatment.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Grupo Argentino de Tratamiento de la Leucemia Aguda portfolio CI brief
- Grupo Argentino de Tratamiento de la Leucemia Aguda pipeline updates RSS
Frequently asked questions about Grupo Argentino de Tratamiento de la Leucemia Aguda
What is Grupo Argentino de Tratamiento de la Leucemia Aguda's pipeline?
Grupo Argentino de Tratamiento de la Leucemia Aguda has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include ARM A: Active Comparator Drug, ARM B: Blocks Therapy Drug.
Related
- Sector hub: All tracked pharma companies